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INTRODUCTION: THE CHALLENGE OF ADHERENCE
Adherence (equivalent to compliance) to lifestyle and med-
ication recommendations for the prevention of cardiovascu-
lar disease (CVD) is a crucial element in the path from the
science of risk-factor modification to the actual reduction of
risk factors and consequent prevention of disease-related
events. Lack of adherence to therapeutic regimens has been
documented for decades, particularly for preventive inter-
ventions requiring changes in behavior such as smoking
cessation, change in eating patterns, physical activity, and
adherence to pharmacologic therapy (1,2). Pharmacologic
industry data (IMS Health; NDC Health Information
Services) document that by the end of one year, adherence
to preventive pharmacologic therapy has dropped to less
than 50% across several broad classes of drugs, including
hydroxy-methyl-glutaryl– coenzyme-A (HMG-CoA) re-
ductase inhibitors and angiotensin-converting enzyme in-
hibitors. Although non-adherence may consist of dropping
therapy altogether, there is also, a significant problem with
individuals who remain in treatment but fail to follow the
treatment regimen in sufficient quantity or appropriate
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intervals to derive the optimal benefit. The patterns of poor
adherence observed among patients remaining in treatment
but adhering poorly (approximately 50% of patients on
treatment) include variability in dosing, dosage interval
errors, reductions in dosage, and excess doses.
Numerous studies have identified factors associated with
poor adherence. With few exceptions (e.g., the conscien-
tiousness scale from the NEO-Five Factor Inventory) (3),
personality traits have not been found to consistently predict
adherence, nor have socio-demographic factors such as
gender, ethnicity, socioeconomic status or education (4).
Negative aspects of the therapeutic regimen itself are the
factors most frequently associated with poor adherence.
These include a long duration of therapy, complexity of the
regimen, therapy of asymptomatic conditions, and a lack of
immediate or perceived benefits, especially when the cost
(either in dollars or in disruption of normal family, social,
and cultural patterns) is high (5). These aspects characterize
many preventive interventions, where lifelong therapy for an
asymptomatic condition may be associated with high cost,
side effects (in the case of medication), and a lack of
understanding of the benefits provided by the behavior
change or therapy. Although motivation may be high in
secondary prevention, the situation is likely to be even more
difficult because behavior change and pharmacologic ther-
apy for risk factors must be added to a regimen that may
already be complex and burdensome.
Effective therapies are now available for the treatment of
hyperlipidemia. A series of studies have documented a
one-third reduction in coronary mortality within 5 years
when patients with coronary heart disease (CHD) are
treated with HMG-CoA reductase inhibitors (statins); and
a favorable effect is seen as early as one year after the
initiation of therapy (6–8). Despite such data, a number of
studies have demonstrated failure to bring the majority of
patients with CHD to their low-density lipoprotein-
cholesterol (LDL-C) target, with the data suggesting that
such failure is related not only to a lack of patient adherence
to prescribed therapy but also to the failure to have appro-
priate therapy prescribed in the first place (9–13). In a recent
study of 825 men and women with CHD followed up at 16
academic medical centers, at the end of a three-year period of
follow-up, 55% of the men but only 35% of the women were
receiving pharmacologic lipid-lowering therapy. The target
LDL-C goal of less than 100 mg/dl was achieved in only 31%
of the men and only 12% of the women. Consistent with
results of other studies, the authors suggest that there may be
a gender bias in the use of such therapy (14).
Taken together and viewed in the context of available
clinical trial data, this information indicates the need for
more effective approaches to adherence, with emphasis on
patients, providers, systems of health care delivery, and
relevant societal factors. Toward that goal, this Task Force
Report presents an overview of the evidence supporting
multilevel strategies for improving the adherence to lifestyle
and pharmacologic interventions. Building on available
adherence data and consistent with the theme of this
Bethesda Conference, suggestions for advancing CVD pre-
vention on both an individual and population level are also
offered.
ADHERENCE: A PROBLEM THAT
MUST BE ADDRESSED ON MULTIPLE LEVELS
Adherence is commonly seen as a patient problem. The
physician (MD) or nurse practitioner (NP) prescribes a
regimen, and it is the patient’s role to follow that regimen.
In 1997, a multidisciplinary task force of the American
Heart Association (AHA) addressed the problem of adher-
ence in a special report, “The Multilevel Compliance
Challenge” (15). This document details the reality that
adherence must be addressed on several levels, including the
patient, the provider, and the health care system. Patients
need the knowledge, attitude, and skills to follow an
appropriately prescribed regimen (16), and similarly, pro-
viders need the knowledge, attitude, and skills to: follow
established guidelines in prescribing that regimen; ensure
that patients understand the reason for the prescribed drugs,
the possible side effects, the interactions with other agents,
and the manner in which the drug is to be taken; and ensure
that the recommended regimen is not unnecessarily com-
plex and is therefore possible to follow. When caregivers do
not follow guidelines, it is often thought that they need
education or training and that the provision of such training
alone will suffice. This is, however, generally not sufficient
(17). Finally, the system or organization within which
providers work needs to provide resources and set policies
that support optimal practices, particularly prevention-
oriented activities (15). These resources can include other
health care professionals as part of the treatment team to
augment the role of primary providers and to provide more
intensive intervention where needed. There is substantial
evidence that the involvement of other health care profes-
sionals to support treatment plans improves the effectiveness
of interventions and increases the prevalence of patient
behavior change or adherence (18). Such resources can
augment the very limited amount of time available to busy
practitioners. Furthermore, policies within organizations
can mandate provision of the following: time for educating
MD/NPs about guidelines; training in treatment strategies
such as patient-centered counseling; dissemination of
guidelines and of appropriate tools that assist in the imple-
mentation of guidelines; and office support mechanisms
(prompts, algorithms, and the setting up of systems to
screen and follow up patients for specific problems such as
elevated lipids) (19).
The patient: factors that affect adherence. The patients
must assume the ultimate responsibility for making behav-
ioral changes, and whether or not a patient adheres to a
prescribed regimen is a complex issue. It is affected by
knowledge, attitudes, skills, and the environment, the health
care provider’s practices, and the health care system (15).
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Research on patient factors that affect adherence has been
inconclusive. As described previously, the relationship of
gender, socioeconomic status, and marital status to adher-
ence is weak and inconsistent (3). However, some relation-
ships have emerged. Organic factors such as the memory
impairment often experienced by CHD patients (20), as
well as the somatic side effects of medications (21–24), can
reduce adherence. Cognitive variables, specifically attitudes
toward medication intake (24,25) and self-efficacy (the
extent to which an individual believes he or she is able to
change a behavior) (4,26–28) have been associated with
adherence to a variety of health behaviors. However, most
studies have been retrospective, and it is unclear whether
these beliefs or expectations predict, or are the result, of
adherence. With regard to affective states, mixed findings
have been reported for the influence of negative affect (e.g.,
depression, anxiety) on adherence to health behaviors. Some
reports suggest that depression and anxiety have a detrimen-
tal influence on adherence (29–32), whereas others have
failed to find such an influence (33–35). Hostility and
conscientiousness, however, two rather stable personality
characteristics, have been shown in several studies to be
associated with adherence. Hostile hypertensive patients
reported skipping more doses of medication than individu-
als with lower hostility scores (31). Likewise, “conscien-
tiousness” (defined as an individual’s determination, persis-
tency, and ability to do what is necessary) has been reported
to correlate with adherence (3,36,37).
The concept of “reasoned decision making” is also rele-
vant. It is thought that patients have no reasonable option
but to comply with the advice and instructions they receive.
Donovan and Blake (38) point out that this concept of
adherence may be irrelevant for patients who carry out a
personal cost-benefit analysis, weighing the costs and risks
of each treatment against the benefits as they perceive them.
Patient perceptions and the personal and social circum-
stances within which they live are shown to be crucial to
their decision-making. Thus, an apparently irrational act of
non-adherence (from a physician’s point of view) may be a
very rational action when seen from a patient’s point of
view. This reasoning leads the authors to encourage the
development of more open, cooperative physician-patient
relationships (38). In a related discussion, Redelmeier et al.
(39) describe patient strategies in which intuitive thought
processes and feelings may lead individuals to make choices
that are not ultimately in their best interests. Such strategies
help to explain situations in which risk perceptions conflict
with standard scientific analyses. The authors suggest that
an awareness of how people reason is an important clinical
skill.
Many patients are unaware of the extent of their deviation
from therapeutic prescriptions. This is reflected in discrep-
ancies between patient’s self-reporting of their treatment
behaviors and monitored reports of those same behaviors
(40). For these patients, it may be necessary to first raise
their awareness of their behaviors. Alternatively, it may be
necessary for providers to present greater detail and speci-
ficity in instructions. Another important factor is the prev-
alence of multiple co-morbidities, leading to treatment
regimens that are particularly complex. Among the older
population, the occurrence of co-morbid conditions is high
(41). Indeed, the risk of poor adherence is higher among
persons with three or more co-morbid conditions (42). A
common example is a patient with type II diabetes, hyper-
tension, and hyperlipidemia.
Patients need knowledge and skills such as problem-
solving, self-monitoring, developing self-prompting and
reminder systems, setting appropriate and realistic goals,
rewarding new behaviors, and identifying lapses (43–46).
As discussed subsequently (and presented in Table 1),
health care providers can help patients identify the
strategies and skills needed and assist patients in building
these skills.
The provider’s role in adherence. There is substantial
evidence that brief provider interventions can have a signif-
icant positive effect on patients’ adherence to a plan and
maintenance of changes in health behaviors such as smok-
ing, diet, and alcohol use (18,47,48). A physician or nurse
can also assist a patient to identify strategies that enhance
adherence to a prescribed regimen. However, caregivers are
often too busy to follow up patients optimally. In this
context, a reminder system and a team approach can provide
assistance. The collective efforts of the multidisciplinary
team also provide the kind of social support (49) that plays
an important role in influencing adherence behaviors
(50,51) and patient satisfaction with care, a significant
predictor of adherence to prescribed regimens (52).
The systems-based factors that affect adherence. The
system within which health care providers work, by either
providing or not providing a supportive environment that
facilitates providers’ adherence-related activities, can mark-
edly alter the likelihood that physicians or nurses will
perform the necessary activities (e.g., prescribing appropri-
ate medication and providing patient-centered counseling
on the use of medication or lifestyle change) (53). Likewise,
systems can help facilitate adherence by providing support
from other health care professionals (e.g., pharmacist sup-
port) and other resources (e.g., databases, tracking systems,
algorithms, prompts, and handouts) (47,54). Approaches to
the problem of adherence that are restricted to the patient
level or the provider level alone are not likely to yield as
successful an outcome as those that also engage the entire
framework within which the provider–patient interaction
takes place (15). As pointed out by Koeck (55), “if care is to
be of higher quality and lower cost, the key to improvement
lies in better organizational structures and processes.” A
final system-based factor is cost itself. This is particularly
true for the cost of medications and for refill policies. Lack
of coverage, high co-payments, and frequent refill require-
ments are all powerful adherence disincentives.
632 Ockene and Hayman et al. JACC Vol. 40, No. 4, 2002
Task Force #4—Adherence Issues and Behavioral Changes August 21, 2002:579–651
COUNSELING AND THEORETICAL MODELS
Several conceptual theories and models of health behavior
change and intervention underlie approaches to adherence.
These models were developed to explain various aspects of
human behavior and have been shown to be predictive of
response to behavioral interventions. They include the
Stages of Change Model (56), the Health Belief Model
(57), Social Cognitive Theory (58,59), the Relapse Preven-
tion Model (60,61), and Social-Ecological Models (62,63),
each of which is briefly described below.
Over the last decade, the Transtheoretical Stages of
Change Model has been applied in research and practice
initiatives focused on individual-level behavior change in
adults, adolescents, and children (56,64–66). Stages-of-
change theory reflects the stages of any behavioral interven-
tion process: pre-contemplation (individual is not thinking
about changing the targeted behavior); contemplation (in-
dividual is considering but is not yet ready to engage in
behavior change); preparation (individual intends to take
action in the next month); action (individual begins the
actual process of behavior change); and maintenance (indi-
vidual develops and implements strategies to prevent re-
lapse). This model has also been applied in conjunction with
other theoretical approaches, including the social cognitive
theoretical model (SCT) and its components (67,68). Cli-
nicians are taught that because change occurs over several
stages, that by correctly targeting their intervention assis-
tance, they can move the pre-contemplator to contempla-
Table 1. Actions to Increase Adherence to Prevention and Treatment Recommendations
Actions by Patients Specific Strategies
Patients must engage in essential prevention and treatment behaviors.
● Decide to control risk factors. ● Understand rationale, importance of commitment.
● Negotiate goals with provider. ● Develop communications skills.
● Develop skills for adopting and maintaining recommended behaviors. ● Use reminder systems.
● Monitor progress toward goals. ● Use self-monitoring skills.
● Resolve problems that block achievement of goals. ● Develop problem-solving skills, use social support networks.
Patients must communicate with providers about prevention and
treatment services.
● Define own needs on basis of experience.
● Validate rationale for continuing to follow recommendations.
Actions by Providers Specific Strategies
Providers must foster effective communication with patients.
● Provide clear, direct messages about importance of a behavior or therapy. ● Provide verbal and written instruction, including rationale for
treatments.
● Develop skills in communication/counseling.
● Include patterns in decisions about prevention and treatment goals and
related strategies.
● Use tailoring and contracting strategies.
● Negotiate goals and a plan.
● Anticipate barriers to compliance and discuss solutions.
● Incorporate behavioral strategies into counseling. ● Use active listening.
● Develop multicomponent strategies (i.e., cognitive and behavioral).
Providers must document and respond to patients’ progress towards goals.
● Create an evidence-based practice. ● Determine methods of evaluating outcomes.
● Assess patient’s compliance at each visit. ● Use self-report or electronic data.
● Develop reminder systems to ensure identification and follow-up of
patients’ status.
● Use telephone follow-up.
Actions by Healthcare Organizations Specific Strategies
Healthcare organizations must
● Develop an environment that supports prevention and treatment
interventions.
● Develop training in behavioral science, office set-up for all personnel.
● Use preappointment reminders.
● Use telephone follow-up.
● Schedule evening/weekend office hours.
● Provide group/individual counseling for patients and families.
● Provide tracking and reporting systems. ● Develop computer-based systems (electronic medical records).
● Provide education and training for providers. ● Require continuing education courses in communication and
behavioral counseling.
● Provide adequate reimbursement for allocation of time for all healthcare
professions.
● Develop incentives tied to desired patient and provider outcomes.
Healthcare organizations must adopt systems to rapidly and efficiently
incorporate innovation into medical practice.
● Incorporate nursing case management.
● Implement pharmacy patient profile and recall review systems.
● Use electronic transmission storage of patient’s self-monitored data.
● Obtain patient data on lifestyle behavior before visit.
● Provide continuous quality improvement training.
Source: Miller NH, et al. The multilevel compliance challenge: recommendations for a call to action. Circulation 1997;95:1085–90.
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tion and the contemplator to action. Thus, patients in the
action stage respond well to forceful encouragement and
support, whereas a patient in the pre-contemplator stage is
likely to be antagonized by an overly forceful approach—in
such individuals the provision of information and a low-key
approach is more likely to be fruitful. It is helpful to remind
health care professionals and patients of this process so that
neither becomes discouraged or alienated from the other.
The SCT model has been applied in both individual and
population-based behavior change strategies focused on
primary and secondary prevention of CVD across the life
span (69–72). It emphasizes interpersonal, cognitive, and
environmental influences on behavior and incorporates
methods of behavior modification. The basic components of
SCT as applied to CVD-related behavior change strategies
(on an individual level) include self-monitoring and analysis
of behavior, self-management (including stimulus control of
external cues), behavioral skill training, replacement of
health-compromising behaviors with health-promoting be-
haviors, and reinforcement of newly acquired desirable
behaviors. Self-efficacy, the individual’s confidence in per-
forming a particular behavior, is an important SCT-related
construct that has been associated with motivation to
engage in health-promoting behaviors in adolescents and
adults (59). The utility and effectiveness of SCT-derived
strategies has been supported in a recent comprehensive
review of the empirical literature focused on adherence
across four regimens of cardiovascular (CV) risk reduction,
including pharmacological therapy, exercise, nutrition, and
smoking cessation (73). Specifically, SCT-derived (and
other theoretically-based) strategies demonstrated to be
successful in improving adherence to CVD-prevention reg-
imens include: signed agreements (written contracts be-
tween patient and physician–provider); behavioral skill
training (formal and informal teaching-learning sessions
focused on patient acquisition of specific skills necessary to
change behaviors); self-monitoring (maintaining a written
record/log of baseline levels and changes over time in
behavior[s] targeted for change); self-efficacy enhancement
(strategies designed to increase patient confidence in the
ability to engage in a particular behavior, such as counseling
small steps that enhance self-efficacy); spouse and/or social
support (inclusion of patient’s spouse or significant other in
the plan for behavior change using principles of direct
modeling of health behaviors [e.g., smoking cessation] and
reinforcement); telephone/mail contact and external cogni-
tive aids (follow-up reminder letters of scheduled or missed
appointments and medication refills).
As emphasized by Burke et al. (73) in the above-cited
review, even in well-controlled and monitored clinical trials
that incorporated theoretically-derived strategies, adherence
is less than optimal and there are significant discrepancies
between adherence rates reported in clinical-trial and
clinical-practice settings. Although the efficacy of CVD risk
reduction programs is well established by clinical trials, the
extent to which primary and secondary prevention is effec-
tive in practice depends largely on adherence. Furthermore,
approximately 50% of individuals discontinue participation
in secondary prevention programs (cardiac rehabilitation)
within the first year; thus, a critical time-period for targeting
adherence-promoting strategies is early in the course of
treatment. While promotion of long-term adherence is a
multilevel, multi-systems challenge, on the individual-
patient level, the sustained application of SCT and other
related strategies by physicians and other health care pro-
viders is associated with improved adherence rates and
treatment outcomes.
On a population level, components of SCT have been
successfully applied to community and school-based CV
health promotion focused on tobacco use, nutrition, and
physical activity behaviors. The multi-center Child and
Adolescent Trial for Cardiovascular Health (CATCH)
emphasized the environmental components of SCT as they
relate to interventions focused on changing the school
health and physical education curricula, school food service,
policies for school tobacco use, and structured activities for
families of CATCH students. The versatility and short-
term effectiveness of SCT-derived school-based environ-
mental interventions was demonstrated.
All of these models can be incorporated in a patient-
centered counseling approach, a style of engaging patients
that has been shown to be efficacious when used to assist
patients in developing and adhering to treatment plans for
risk-behavior change (e.g., smoking, high-fat diet, and
high-risk alcohol use) (47,48,54). This approach uses tele-
phone counselors to help treat patients for smoking (74,75)
and nutritionists to help patients make dietary change.
Patient-centered counseling also responds to recommenda-
tions emphasizing the need for providers to use open-ended
questions to engage patients in decision making (38,39). It
encourages health care professionals to ask patients about
their perception of risk and to help them weigh costs and
benefits of change or of adherence to a regimen. Patient-
centered counseling is also designed to be time-efficient.
This model uses questions related to five content areas: 1)
desire and motivation to change behavior; 2) past experi-
ences with the behavioral change; 3) factors that inhibit the
change (barriers/impediments); 4) resources for change
(strengths); and 5) the plan for change and follow-up. It
emphasizes the use of past experiences of change to help
patients develop motivation and positive self-efficacy. As in
the Health Belief Model, patient-centered counseling ad-
dresses an individual’s beliefs regarding the perceived risk
associated with certain behaviors, his or her vulnerability to
worsening disease, and the taking of action to change
behavior in order to decrease the risk.
Principles of the Relapse Prevention Model (60,61) are
also important in counseling. They include stressing the
need to recognize cues and characteristics of high-risk
situations (assessment skills) and to develop specific skills
(e.g., communication, initiation of support, stress manage-
634 Ockene and Hayman et al. JACC Vol. 40, No. 4, 2002
Task Force #4—Adherence Issues and Behavioral Changes August 21, 2002:579–651
ment) to mobilize a coping response to promote behavioral
change.
Intervention at the level of the health care system, no
matter how well delivered, does not account for the influ-
ence of the larger society within which we all live. Main-
taining healthy behaviors over time (e.g., during the tran-
sition from the school-age years to adolescence and into
adulthood, or over many years of disease-free life) requires
system changes that go beyond the family and school level.
Social-ecological models that address multilevel system
changes have recently been advocated to address this goal
(62,63,76,77).
Ecological frameworks recognize that behavior is affected
by several levels of influence including: intra-personal fac-
tors (e.g., motivation, skills, knowledge); interpersonal pro-
cesses (e.g., social support, social network, social norms);
institutional or organizational factors (e.g., school and/or
workplace policies); community factors (e.g., social capital
and neighborhood effects); and public policy (e.g., regula-
tory laws and tobacco taxes). By definition and design,
ecological models suggest that interventions must be di-
rected at all of these factors. Central to each of the
ecological frameworks that have recently emerged across
disciplines is the importance of social context. In relation to
adherence and CVD-prevention strategies, ecological mod-
els strongly suggest that interventions be focused beyond the
individual patient, provider, and respective system of health
care. A systematic integration of social, governmental, and
policy-level factors into behavior-change interventions
within communities is suggested as one ecologically-derived
approach. Thus, for example, increasing physical activity in
urban areas requires at least safe streets and adequate parks,
recreation areas and lighting. Ultimately improving health
may require societal interventions such as the redesigning of
streets and elimination of drive-up windows—changes not
amenable to patient, physician, or medical-system interven-
tion. Even beyond this, there are powerful societal trends
whose reversal seems difficult to envision. An example of
such trends is described by Philipson and Posner (78), who
note that over a period of many decades in the U.S., food,
which used to consume a large part of a family’s budget,
has become very cheap (a few dollars will buy a day’s
worth of high-fat calories at a fast food restaurant),
whereas physical activity, once something most adults
were paid to do (because most jobs were physically
demanding) has become quite expensive, either literally
as dollars spent or as time, an equally valuable commodity
for many people.
Optimally, approaches in individual-level behavior
change should be integrated within population-based ap-
proaches that take into account the ecologic framework
within which the intervention is planned to occur and
should be linked across delivery channels. Thus, CVD-
prevention programs offered through an individual’s em-
ployee benefits programs could be promoted through inter-
ventions at the workplace. These, in turn, could be linked to
local and statewide preventive efforts through departments
of health. By design, these initiatives in prevention would
require policy changes on a number of levels, including the
workplace. Early in 2001, the White House issued an
executive memorandum directing agencies to review, revise,
and establish policies as necessary to maximize federal
employees’ participation in agency-sponsored preventive
health activities. The directive included the formulation of a
policy providing for excused absences each year for partici-
pation in preventive health screenings.
GENERAL STRATEGIES FOR INCREASING ADHERENCE
Strategies for increasing adherence with prevention and
treatment recommendations have been studied over the past
twenty-five years. As discussed before, recent literature
supports a multilevel approach, including an emphasis on
patients, providers, and systems and health care organiza-
tions (15,79). Effective interventions use a variety of behav-
ioral, cognitive, and educational strategies. On the patient
level, skills such as problem-solving, self-monitoring, devel-
oping prompts or reminder systems, identifying a risk for
relapse to a former behavior, enlisting social support, setting
appropriate and realistic goals, and rewarding achievement
of new behaviors are useful in a variety of situations (15).
Adherence is augmented the most when a combination of
strategies is used.
As a first step, the patient must recognize that adherence
is a problem. This will be obvious when the patient has
completely stopped treatment or a component of treatment.
However, it is more common for a patient to adhere only
variably and be unwilling to report the variability or unaware
to what extent this is a problem. For patients not having the
desired treatment outcome (e.g., a lower blood pressure
[BP] after being prescribed an antihypertensive agent) and
who deny adherence problems, it can be very useful to
review refill records or at least have the patient bring in the
medication containers so that refill dates can be reviewed.
Other options such as electronic monitors or electronic
diaries can be of value if they are available. Medication,
exercise, diet, and glucose monitoring can all be examined
by using such technologies.
Once adherence problems have been identified, effective
communication between patients and health care providers
is essential and forms the basis for the actions and strategies
detailed in Table 1. Providers, including physicians, nurses,
pharmacists, health educators, nutritionists, and psycholo-
gists, may promote adherence through education, motiva-
tion, monitoring, and feedback. Evidence supports the use
of the following:
● simplifying the regimen
● tailoring the regimen to the patient’s lifestyle and needs
● asking the patient about adherence at every visit
● having the patient bring in medication containers and
reviewing them together, with attention to renewal dates
as a marker of adherence
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● involving the patient as a partner in the treatment process
● providing clear written and oral instructions
● using behavioral strategies such as reminder systems,
cues, self-monitoring, feedback, and reinforcement.
Additional training may be needed to enable providers to
offer effective counseling for interventions. Examples of this
would be strategies developed for smoking cessation and
nutritional change (80,81). In general, considering a pa-
tient’s level of change and need to improve self-efficacy,
counseling should often take a gradual step-by-step ap-
proach to improving adherence, particularly when the pa-
tient needs to adhere to recommendations in several areas.
However, individuals such as Dean Ornish (82) have argued
that for many patients, particularly those in secondary
prevention mode, a better response can be obtained by
challenging her or him to make large changes that produce
measurable beneficial results, not only in terms of laboratory
measurements but also in terms of symptoms. This has been
demonstrated in studies such as the Multicenter Lifestyle
Demonstration Project (82), in which an intensive multi-
factorial intervention of comprehensive lifestyle change was
studied as a direct alternative to revascularization in selected
patients. In this study, 77% of the experimental group of
patients were able to avoid revascularization for at least three
years without increasing cardiac morbidity or mortality. The
patients reported reductions in angina comparable to that of
which could be achieved with revascularization. Such an
approach can be very fruitful when applied to appropriately
motivated patients (82,83).
Telephone counseling (TC) can be an important adjunct
to direct counseling and is an effective mechanism for the
simultaneous addressing of educational, psychosocial, and
practical barriers to adherence (84). An important study of
the adjunctive use of TC to aid risk-factor management in
patients with CHD was carried out by DeBusk et al. (85).
They developed a physician-directed, nurse-managed, case
management system for risk-factor modification and, in a
randomized controlled trial, compared the results with those
of usual medical care. The intervention was done on
smoking, nutrition, exercise, and lipid-lowering therapy and
showed significant improvement in several areas of lifestyle
behavior. Another study supporting the efficacy of TC was
designed to improve the dietary self-care of diabetics (86).
Patients received TC calls 1 week and 3 weeks after their
physician visit, in combination with immediate computer-
generated feedback, a 20-min meeting with an intervention
staff member, a copy of a mutually developed goal-setting/
strategy worksheet, a self-help pamphlet in which sections
relevant to their goal had been highlighted, and videos
aimed at enhancing self-efficacy. This brief intervention
resulted in significant differences in cholesterol levels at the
three-month follow-up.
There is substantial support for TC in smoking interven-
tion. Ockene et al. (75,87) demonstrated a significant
improvement in smoking cessation rates when a TC proto-
col was used to counsel smokers with CHD. Orleans et al.
(88) found that TC intervention increased the use of
self-help materials, and yielded significantly higher short-
and long-term cessation rates. Likewise, in a study by
Lando et al. (89) the use of two TC calls (averaging less
than 15 min each) led to significant differences in validated
six-month cessation rates. A meta-analysis of TC for
smoking cessation also supports the effectiveness of coun-
seling calls both at short- and long-term follow-up (90). In
one cited study, there was a dose-response effect, with six
calls being more effective than one, which was in turn more
effective than written materials. Telephone counseling calls
have been well received in a number of studies
(54,75,91,92).
Health care organizations can influence the provision of
preventive and treatment services through the establishment
of tracking and reporting systems, the provision of educa-
tional and training programs, and the appropriate reim-
bursement of providers (15). The ability to incorporate
innovations into medical practice has also been associated
with changes in practice behavior and positive patient
outcomes (80,85). Professional and governmental organiza-
tions have established web sites to disseminate valuable
information and tools for patients, health care professionals,
and health care organizations to assist in developing and
maintaining successful health programs. The AHA (www.
americanheart.org) Compliance Action Program includes
AHA Guidelines, a Patient Tracking Form to track CVD
risk factors for patients, risk-factor patient information
sheets, and many other resources. The AHA has also
launched a robust, web-based, tailored behavior-change
program called “My Heart Watch” (http://www.
myheartwatch.org) as well as several sites for specific risk
factors such as elevated cholesterol and physical inactivity.
Web sites of the individual institutes that comprise the
National Institutes of Health (NIH) provide a remarkable
array of resources. The National Heart, Lung, and Blood
Institute (NHLBI) (http://nhlbi.nih.gov), can be accessed
for instruments to manage risk factors, including hyperten-
sion, hypercholesterolemia, and obesity. In addition, The
National Diabetes Education Program (http://ndep.
nih.gov/), a partnership of the NIH, the Centers for Disease
Control and Prevention, and over 200 public and private
organizations, offers information on diabetes control.
RISK-FACTOR-SPECIFIC STRATEGIES AND
RESOURCES FOR INCREASING ADHERENCE
Smoking. There are many effective approaches for smok-
ing cessation. One is the Patient Centered Counseling
Program developed by Ockene et al. (54). Another is
detailed in the “Quick Reference Guide for Smoking
Cessation Specialists” (18).
Briefly, approaches for smoking cessation should include
the following:
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● Ensure that all persons are aware of the health hazards of
cigarette smoking by using posters/handouts in the wait-
ing room.
● Query all persons regarding their smoking habits on every
visit.
● Explore barriers to and resources for smoking cessation.
● Provide targeted and negotiated counseling according to
a patient’s level of knowledge, stage of readiness for
change, and assessment of resources/barriers.
● Consider the use of smoking cessation aids that have
proven useful in the setting of a counseling approach:
nicotine-containing patches, gum, or inhalers; bupro-
prion.
● Schedule follow-up visits to discuss a patient’s progress in
addressing smoking cessation.
Hypertension. One risk factor for which adherence to
medication-taking has improved, although it is not yet
optimal, is hypertension. Evidence-based recommendations
exist to guide the provider (93,94). Programs in which
multidisciplinary teams address patients’ beliefs and con-
cerns and provide follow-up, feedback, and free medication
if needed are the most successful. Practitioners should
follow The Sixth Report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure (JNC VI) guidelines for the detection, eval-
uation, and treatment of persons with high BP (93).
Diet/hyperlipidemia. The recently published Third Re-
port of the Expert Panel on Detection, Evaluation, and
Treatment of High Blood Cholesterol in Adults (95) (ATP
III) suggests multilevel interventions designed to improve
adherence to the evidence-based guidelines for the assess-
ment and management of dyslipidemias and other risk
factors in individuals with CHD and at-risk for CHD. The
complete report is available from the NHLBI website
(www.nhlbi.nih.gov).
These can be summarized as follows for all patients:
● Briefly assess dietary intake of saturated fat and choles-
terol.
● Promote U.S. Dietary Guidelines (population diet) using
pamphlets/handouts and Food Guide Pyramid. Empha-
size food portions.
● Provide shopping and food preparation pamphlets/hand-
outs highlighting low-saturated fat foods, including
reduced-fat dairy products, leaner meats, lower-fat
ground meat, and reduced-fat baked goods.
● Make full use of office personnel to promote public health
message.
The following summary is for hyperlipidemic patients:
● Consider readiness to change and level of motivation.
● Promote ATP III therapeutic lifestyle changes diet using
individualized diet counseling that provides acceptable
substitutions for favorite foods contributing to a patient’s
elevated LDL level—counseling often best performed by
a registered dietitian.
● Reinforcement of dietary principles during follow-up
visits at which LDL response to diet is assessed.
Obesity. A practical guide for the “Identification, Evalua-
tion, and Treatment of Overweight and Obesity in Adults,”
www.nhlbi/cardiovascular/obesity, is an evidenced-based
report designed to assist health care practitioners in provid-
ing patients with the direction and support needed to lose
weight and maintain the weight loss. Ten suggested steps
for treating overweight and obesity in the primary care
setting follow:
1. Measure height and weight.
2. Measure waist circumference.
3. Assess co-morbidities.
4. Should your patient be treated?
5. Is the patient ready and motivated?
6. Which diet should you recommend?
7. Discuss a physical activity goal.
8. Review the Weekly Food and Activity Diary.
9. Give the patient copies of the dietary information.
10. Enter the patient’s information.
The most significant problem in the treatment of indi-
viduals who are overweight or obese, but who have lost
weight, is the maintenance of behaviors that led to the
weight loss (96,97). Several studies have focused on strate-
gies for improving the maintenance of weight loss. A review
of the strategies shown to be effective in enhancing long-
term weight maintenance was reported by Burke (98).
Ongoing contact between a health care professional and a
patient yielded the most consistent improvement in main-
tenance. Ensuring that the individual incorporates regular
physical activity into the weight loss program is also
essential for long-term success. Individuals who had strong
social support while participating in a weight loss treatment
program showed improved adherence to the program and
greater weight loss and maintenance than those who were
pursuing treatment alone (99). These strategies highlight
the need to view the treatment of obesity in the context of
a chronic disorder, similar to hyperlipidemia, wherein an
individual needs ongoing follow-up, evaluation, and rein-
forcement.
Diabetes. Numerous resources are available to assist pa-
tients, providers, and organizations, including work-sites in
the control of diabetes (http://ndep.nih.gov/materials/pubs/
making-a-difference/making-a-difference.pdf). For diabetic
patients, the recommendations listed under the obesity,
physical activity, and diet headings are especially pertinent.
Physical activity. Programs to promote physical activity
are available and feasible. Prochaska et al. (100,101) de-
scribe a particularly interesting program using interactive
health communication technologies designed to promote
physical activity and healthy nutrition for adolescents and
adults that can be incorporated into clinical settings
(Patient-centered Assessment and Counseling for Exercise
plus Nutrition [PACE] programs). At a minimum, phy-
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sicians, nurse-practitioners, and other providers should do
the following:
● Promote regular physical activity by taking a physical
activity history.
● Provide pamphlets/advice regarding general principles of
physical activity.
● Recommend 30 min a day of regular, moderate-intensity
activity.
Medication-taking behavior. On the simplest level, the
provider should always ask about adherence to medication
and should encourage patients to bring in medication
containers for a review of refill dates. If available, use of an
electronic medication event monitoring system provides
unobtrusive monitoring of day and exact time of
medication-taking events and provides more reliable infor-
mation about adherence than pill counts or self-reporting.
Selected strategies identified in Tables 1 and 2 are also
applicable to medication-taking behavior.
SUMMARY AND FUTURE DIRECTIONS
In the past decade, considerable attention has focused on
the central and essential role of adherence as it relates to
primary and secondary prevention of CVD. Although
adherence awareness and recognition of the need for mul-
tilevel approaches have increased, accumulated data suggest
that progress has been quite variable—particularly with
adherence to preventive interventions. This is true despite
growing evidence regarding the efficacy of preventive and
therapeutic regimens designed to reduce the risk and burden
of CVD. Our most impressive achievements have been in
smoking cessation, and considerable progress has also been
made in controlling high BP and reducing the population’s
intake of fat and saturated fat. On the other hand, the
percentage of the population that is obese continues to rise,
and average physical activity levels continue to decline. In
addition, there is substantial evidence that individuals are
substituting sugar for fat in their diet. Perhaps as a conse-
quence, there is an epidemic of diabetes. As Claude Len-
fant, Director of the NHLBI has noted, “the real challenge
of this new millennium may indeed be to strike an appro-
priate balance between the pursuit of exciting new knowl-
edge and the full application of strategies known to be
extremely effective, but considered underused” (102).
Adherence-enhancing research, focused on all three lev-
els—the patient, the provider, and the system—has been
increasingly emphasized over the past decade. This line of
inquiry has contributed important knowledge to our under-
standing of patient and provider behaviors as well as issues
embedded within our health care system. Although there is
controversy regarding targeted areas for future adherence
research, there is also consensus regarding the need to
disseminate and apply in practice the multilevel strategies
associated with adherence-enhancement. Achieving a long-
term solution will require more emphasis on the multilevel
contexts that influence the development and maintenance of
prevention-related health behaviors. To achieve the CVD-
prevention goals on a population level, mechanisms for the
systematic integration of social, health, governmental and
policy-level factors must be added to individual-level ap-
proaches.
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